March 16 (Reuters) - Nasus Pharma Ltd NSRX.A:
NASUS PHARMA ANNOUNCES POSITIVE TOP LINE DATA FROM PHASE 2 CLINICAL STUDY OF NS002: ACHIEVES SIGNIFICANTLY SUPERIOR AND FASTER EPINEPHRINE DELIVERY COMPARED TO EPIPEN® WITH ACCELERATED SPEED TO THERAPEUTIC THRESHOLD
NASUS PHARMA LTD - NS002 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS
NASUS PHARMA LTD - NS002 ACHIEVES MEDIAN T100 OF 1.69 MINUTES VERSUS 3.42 MINUTES FOR EPIPEN
NASUS PHARMA LTD - PIVOTAL STUDY INITIATION PLANNED FOR Q4 2026
NASUS PHARMA LTD - NS002 REACHES MEDIAN PEAK CONCENTRATION IN 15 MINUTES VERSUS 19.8 MINUTES FOR EPIPEN